A CLINICAL STUDY TO ASSESS THE EFFICACY OF EPIPHEGUS VIRGINIANA 30C IN REDUCING MIGRAINE - RELATED DISABILITY USING THE MIDAS SCALE

Null Hypothesis:

Epiphegus Virginiana 30C has no significant effect on reducing migraine-related disability as measured by the MIDAS Scale.

Alternative Hypothesis:

Epiphegus Virginiana 30C significantly reduces migraine-related disability as measured by the MIDAS Scale.

Aim:

The aim of this study is to evaluate the efficacy of Epiphegus Virginiana 30C in reducing migraine-related disability, as measured by the MIDAS (Migraine Disability Assessment) Scale.

Objectives:

To assess the effectiveness of Epiphegus Virginiana 30C in the management of migraines.

To measure improvements in migraine-related disability using the MIDAS Scale.

Source of Data:

Study participants will be recruited from the OPD (Outpatient Department), peripheral OPD, and IPD (Inpatient Department) of A.M. Shaikh Homoeopathic Medical College, Hospital, and Post Graduate Research Centre, Belagavi.

Type of Research:

This is a prospective interventional single-arm clinical study.

Sampling Technique and Method:

The study will use a purposive, non-probability sampling method.

Selection Criteria:

Participants will be selected based on criteria supported by the International Headache Society (IHS).

Duration of Study:

All selected subjects will be enrolled within 15 months.

Tools Used in Study:

Standard case proforma.

Informed consent form.

MIDAS Questionnaire to assess migraine-related disability.

Inclusion Criteria:

Participants aged 18–60 years.

Diagnosed with migraine and having a history of the condition.

Exclusion Criteria:

Patients with headaches other than migraine.

Those currently undergoing long-term allopathic migraine treatment or using other anti-migraine medications.

Remedy Prescription Criteria:

All 36 cases will be treated with Epiphegus Virginiana 30C, prescribed according to the acute or sector totality of the case.

Follow-Up:

Follow-up will be conducted every month for a period of 3 to 6 months, based on the requirements of the individual case.

Result Criteria:

An improvement will be defined as a reduction of 10 or more points in the MIDAS score, indicating a significant decrease in migraine-related disability.

This study aims to assess whether Epiphegus Virginiana 30C offers a viable homeopathic treatment option for reducing the impact of migraines on daily functioning.